Jove
Visualize
Contact Us

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Overall Survival And Prognostic Factors In De Novo Metastatic Human Epidermal Growth Factor Receptor (her)-2-positive Breast Cancer: A National Cancer Database Analysis.
  1. Home
  3. Overall Survival And Prognostic Factors In De Novo Metastatic Human Epidermal Growth Factor Receptor (her)-2-positive Breast Cancer: A National Cancer Database Analysis.

Related Experiment Video

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

8.9K

Overall Survival and Prognostic Factors in De Novo Metastatic Human Epidermal Growth Factor Receptor (HER)-2-Positive

Meghana Kesireddy1, Durva Masih1, Valerie K Shostrom2

  • 1Division of Hematology and Medical Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Cancers
|June 13, 2025

View abstract on PubMed

Summary
This summary is machine-generated.
Keywords:
Cox proportional hazard modelclinicopathological factorsdemographic factorsmetastatic HER2-positive breast cancermultivariate analysisnational cancer databaseoverall survivalprognostic factorstreatment factors

More Related Videos

Surgical Procedures and Methodology for a Preclinical Murine Model of De Novo Mammary Cancer Metastasis
08:41

Surgical Procedures and Methodology for a Preclinical Murine Model of De Novo Mammary Cancer Metastasis

Published on: July 29, 2017

13.9K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.0K

Related Experiment Videos

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

8.9K
Surgical Procedures and Methodology for a Preclinical Murine Model of De Novo Mammary Cancer Metastasis
08:41

Surgical Procedures and Methodology for a Preclinical Murine Model of De Novo Mammary Cancer Metastasis

Published on: July 29, 2017

13.9K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.0K

This study identified key factors impacting survival for de novo metastatic HER2-positive breast cancer patients. Understanding these prognostic indicators can personalize treatment and improve outcomes for HER2-positive breast cancer.

Area of Science:

  • Oncology
  • Medical Statistics

Background:

  • HER2-positive breast cancer accounts for 15-20% of cases.
  • De novo metastasis occurs in 3-10% of patients, with survival heterogeneity despite anti-HER2 therapies.

Purpose of the Study:

  • To identify prognostic factors for overall survival (OS) in de novo metastatic HER2-positive breast cancer.
  • To utilize a large cohort from the National Cancer Database (NCDB) for robust analysis.

Main Methods:

  • Analysis of 5376 women with de novo metastatic HER2-positive breast cancer (2010-2020) from the NCDB.
  • Kaplan-Meier curves and Cox proportional hazard models were used to assess OS and identify significant prognostic factors.

Main Results:

  • Median OS was 55.95 months.
  • Multivariate analysis revealed age, comorbidity score, histology, HER2 IHC, hormone receptor status, metastatic sites/location, and various treatments (chemotherapy, anti-HER2, hormone therapy, surgery, palliative care) significantly impacted OS.

    • Conclusions:

    • This is the largest real-world analysis of OS in de novo metastatic HER2-positive breast cancer.
    • Identified independent prognostic factors can aid in individualizing prognostication and treatment strategies.
    • Findings support patient stratification for future clinical trials.